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A B S T R A C T
Background: Aside from the fully licensed herbal medicines there are products on the European pharmaceu-
tical market which are registered by virtue of their longstanding traditional use. The normal registration
procedure does not apply to them because presently they do not meet the legal requirements for a full license as
set out in the relevant European Union Directive. One of these requirements, “proof of tradition”, has so far
been dealt with in diﬀerent ways and fails to meet the criteria of good practice.
Method: This analysis is based on a selective literature search in PubMed and in databases of medical and
pharmaceutical history, interviews with licensing experts, a consensus meeting attended by researchers with a
background in general medicine, phytotherapy, medical and pharmaceutical history, biometry, ethnopharma-
cology, pharmacognosy and the pharmaceutical industry.
Results and discussion: The 2004 EU Directive, which governs the registration of Traditional Herbal Medicinal
Products and demands proof of tradition, is a regulatory construct and, above all, the outcome of a political
process that has ended in a pragmatic compromise. The concept of tradition applied in the Directive does not
suﬃciently reﬂect the semantic breadth of the term. The only condition deﬁned is that a speciﬁc commercial
preparation needs to have been on the market for 30 years (15 of them inside the EU). Such an approach does
not make full scientiﬁc use of the evidence available because the information excerpted from historical sources,
if adequately processed, may yield valuable insights. This applies to indications, modes of application, eﬃcacy
and product safety (innocuousness). Such criteria should enter in full into the beneﬁt-risk-analysis of applied
preparations, in the registration process as well as in the therapeutic practice.
Conclusion: When registering Traditional Herbal Medicinal Products the criterion of evidence-based medicine
will only be met if all the facts available are assessed and evaluated, over and above the formally stipulated
regulatory provisions (30 years, product reference). To this end, the scientiﬁc methods (from among the natural,
life or cultural sciences), which are recognized as authoritative in each case, must be applied.
1. Introduction
In many countries of the EU and beyond (e.g. Australia), herbal
medicines are used based on a tradition of use. For example, seventy
per cent of German people have used ‘natural medicines’ (Allensbach
Survey, 2017) with herbal preparations being the most commonly used
type. In Germany alone, herbal medicines worth 1.36 billion market
data were sold in 2015 without prescription, by mail order or in
pharmacies (IMS Health OTC® Report, 2015). Aside from the fully
licensed medicines, there are also products which are registered as
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traditional medicines on the strength of their longstanding use. In the
context of ethnopharmacology, this poses some core challenges, most
importantly with regards to how to build an evidence-base for the use
of such products speciﬁcally with regards to deﬁning what constitutes a
tradition of use as a medicine.
2. Regulatory procedures and proof of eﬃcacy
In 2004 a European Union Directive (Directive, 2004/24/EG) was
passed in order to address the growing demand for Traditional Herbal
Medicinal Products (THMP), which do not fall within the scope of the
normal regulatory procedure because they do not provide the proof of
eﬃcacy that is legally required for a full license, and also in order to
“ensure the greatest possible protection of public health”
(Stellungnahme, 2003), as requested in a statement of the Economic
and Social Committee of the European Parliament. Today, the
European Union member states use this Directive as a guideline for
registering herbal medicines for self-medication. These herbal medi-
cines must have a suﬃciently established tradition and be proven to be
safe enough to be placed on the over-the-counter (OTC) market
(Vlietinck et al., 2009). Concrete evidence must be provided for the
product not being “harmful in speciﬁed conditions of use and that the
pharmacological eﬀects and the eﬃcacy of the medicinal product are
plausible on the basis of longstanding use and experience”. As part of
such evidence “proof of tradition” needs to be supplied, which Article
16c (1c) deﬁnes as “bibliographical or expert evidence to the eﬀect that
the medicinal product in question, or a corresponding product has been
in medicinal use throughout a period of at least 30 years, including at
least 15 years within the Community [i.e. within the European Union]”.
Since 2004, this European Directive has been incorporated into the
national legislations of the EU member states. In the Federal Republic
of Germany, for instance, the clause is almost literally included in
Section 39b of the Medicinal Products Act (Arzneimittelgesetz, AMG,
cf. notiﬁcation of 12/12/2005): “Applicants are required to submit with
their application for registration the following information and doc-
umentation; […] 4) bibliographical or expert evidence to the eﬀect that
the medicinal product in question, or a corresponding product, has – at
the time of application – been in medicinal or veterinary-medical use
throughout a period of at least 30 years, including at least 15 years
within the European Union, that the medicinal product is not harmful
in speciﬁed conditions of use and that the pharmacological eﬀects and
the eﬃcacy of the medicinal product are plausible on the basis of long-
standing use and experience” (Arzneimittelgesetz, 2005).
This regulatory construct (including the timeframe it speciﬁes) is
primarily the result of a political process and, therefore, constitutes a
pragmatic compromise. It reﬂects the eﬀorts at EU-level to create a
harmonized legal framework for this section of the medicines market,
too. However, the Directive uses a concept of tradition which fails to
reﬂect the complex semantic breadth of the term and, therefore, does
not fully exploit the scientiﬁc evidence available. With this article, we
demonstrate how – using the appropriate scientiﬁc methods – this can
be resolved and how additional evidence can be created as a result. The
arguments in the paper are relevant both in the context of ascertaining
best practice in the use of herbal medicines, but also are of wider
relevance in the context of ethnopharmacology, exemplifying problems
with how such uses are labelled as ‘traditional’.
3. A vague concept of tradition
The concept of “traditional use” is not explained anywhere in the
legal provisions. The law itself merely deﬁnes criteria that need to be
met if medicines are to be registered as a THMP, such as the apparently
arbitrary temporal speciﬁcation (“at least 30 years, including at least 15
years in the European Union”). The main underlying intention was, it
seems, to harmonize for the Common Market the various traditions of
use applied for herbal medicines in Europe – based on the criteria of
longstanding and, above all, safe use (Kügel et al., 2016, 707). As is
apparent from the relevant legal commentary, the required form and
content of such documentation, therefore, are subject to legal require-
ments (Kloesel and Cyran, 2004, 124).
The multiple layers of a concept as colourful as “tradition” have, so
far, not been taken into consideration. In view of the semantic
problems raised by this concept, especially in the medical context, it
seems appropriate brieﬂy look at the way the term is used in other
disciplines (sociology, anthropology, history and philosophy) in order
to gain insights for using it in the context of medicine.
In sociology above all the work of Edward Shils (1910–1995) needs
to be mentioned. For Shils, tradition is primarily a formal process of
transmission (“anything which is transmitted or handed down from the
past to the present” (Shils, 1981, 12)). This process can involve
material objects as well as practices. The decisive factor is that they
have been or are being transmitted. According to Shils, an industrial
production process in itself (this applies also to the manufacture and
marketing of a medicinal product at an earlier point in time) does not
yet create a tradition; for it to become tradition the process needs to be
transmitted, or ritualized. Repetition, or “re-enactment”, is conse-
quently an indispensable precondition for tradition. Transmission
has to proceed in several stages and, as a rule, cover two to three
generations (Shils, 1981, 16; Weick, 1995, 124).
From among the many ethnological theories the approach intro-
duced by Richard Handler and Jocelyn Linnekin are particularly
relevant to our context. Both of them see tradition as symbolic
construction and representation. Tradition, in their view, does not
simply mean handing down. It involves initial construction followed by
continual transformation through interpretation. Handler and
Linnekin speak of a “paradox of tradition” (Handler and Linnekin,
1984). Tradition can also be “invented”, as Eric Hobsbawm (1917–
2012) and Terence Ranger (1929–2015) demonstrate in their ideology-
critical studies (Hobsbawm and Ranger, 1992). The most accessible
example of an invented tradition are folk garments. Such costumes are
not time-honoured traditions but rather a nineteenth century phenom-
enon. They are not examples of what farmers used to wear for work or
for festive occasions but reﬂect the interest of city-dwellers in the rural
population and its customs.
In history the term “tradition” has been used since Johann Gustav
Droysen (1808–1884) to describe the conscious transmission of
contents, for instance in memoirs or other ego-documents (Brandt,
1958, 56ﬀ.). These need to be diﬀerentiated from “remnants”, which
are unintentionally passed-down testimonials of historical occurrences,
such as legal or everyday texts, buildings, objects, but also abstract
documents of human coexistence such as language, customs and
rituals. This diﬀerentiation, as will be explained below, is particularly
important when it comes to historical evidence (for example a critical
assessment of sources).
Even more relevant to our regulatory context is the concept of
“social validation” advanced by John K. Crellin, the Canadian historian
of medicine and pharmacy, in order to deﬁne the tradition of
complementary-medical therapies more precisely. According to
Crellin, a tradition is “the more valid” the further it can be traced into
the present and the more ubiquitous it is in geographically separate
regions. Other factors, such as the usefulness experienced by patients,
also inform this matrix of evaluation (Crellin, 2001).
Philosophers, too, have given thought to the concept of tradition.
According to Hans Blumenberg (1920–1996) a tradition does not
consist of “relics, but of attestations and legacies” (Blumenberg, 1981,
375). In other words, tradition does not refer to some remnants of the
past nor does it emerge by itself but through inheritance or aﬃrmation
(Assmann, 1994). Such a cultural inheritance, which is passed down
from generation to generation, can comprise scientiﬁc knowledge and
workmanship as well as artistic conceptions, behaviours and values.
Another philosophical approach derives from Jürgen Habermas’
Theory of Communicative Action (Dittmann, 2004, 323ﬀ.). In order
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to resolve the relatively common problem of contradicting traditions,
communicative methods can be employed that allow everyone involved
to participate in the process of conﬂict resolution. Karl Popper (1902–
1994) was the ﬁrst to establish a rational foundation for tradition
(Popper, 1972). Starting from the idea of the “living tradition”, it also
oﬀers a solution to the problem of authenticity (Beckstein, 2017).
Even though the humanities and social sciences have diﬀering
concepts of tradition, these concepts tend to have one characteristic in
common: If the concept is to be meaningful at all, a tradition, in the
sense of a cultural inheritance, must take account of social dynamics
and, therefore, span at least two generations. Assuming a generational
interval of 30 years amounts one would have to take 60 years as a
minimum, a very long period in today's progress-oriented medicine.
Therefore, it has not found access into the EU Directive on THMP or
the subsequent German Medicinal Act. However, (medical-)ethnologi-
cal research as well as pharmacological research, which is inﬂuenced by
the former, point to the need to consider longer periods of time, even if
such a consideration does not amount to proof of tradition under the
medicinal regulation. For example, the 2015 Nobel Prize for Medicine
which was awarded to the Chinese scientist Youyou Tu based on a
discovery linked to meticulous botanical-historical research (Tu, 2016;
Unschuld, 2015). In the 1960s Ms Tu and her colleagues began to
search the ancient Chinese literature for references to substances which
have proven eﬀects in cases of malaria. They ﬁrst selected from the
numerous historical sources a large number of medicinal plants,
including Artemisia annua L. The annual common wormwood was
ﬁrst mentioned for the treatment of malaria in the recipe collection of
the renowned Chinese scholar Ge Hong (284–364 C.E.), and this
speciﬁc application is documented again and again over a period of
almost 1700 years. The Chinese research team also discovered essential
references in this source to the extraction procedure and, therefore, to
the isolation of the active metabolite artemisinine. Clinical studies
provided positive proof of the substance's eﬃcacy. Today, artemisinin
is a clinically essential antimalarial medicine uses throughout Asia,
Africa, and Southern America.
The terminology used in the EU Directive – or in the German
Medicines Act – does not necessarily conform to (nor is it required to in
this context) the concept of tradition used by the World Health
Organization (WHO): “Traditional medicine is the sum total of knowl-
edge, skills and practices based on theories, beliefs and experiences
indigenous to diﬀerent cultures that are used to maintain health, as
well as to prevent, diagnose, improve or treat physical and mental
illnesses” (WHO Traditional Medicine Strategy 2014–2023). This
deﬁnition refers to culture-speciﬁc medical systems with traditions
going back hundreds if not thousands of years (in China or India, for
instance) and coincides with the commonly accepted interpretation of
tradition as culturally inherited. The ethnopharmacological studies
underlying these concepts have, however, rarely been subjected to
historical scrutiny. Instead, “traditional medicine” is equated one-
sidedly and synchronously with the forms of therapy practised locally
and in the present (Heinrich, 2006; Lardos, 2015). Often this inter-
pretation is limited to orally transmitted traditions, even if these have
been inﬂuenced by written traditions for hundreds of years (Leonti,
2011).
4. Problems in regulatory practice
The development of the “proof of tradition” is represented within
the framework of the THMP registration is shown in the Assessment
Reports of the Committee on Herbal Medicinal Products (HMPC) of
the European Medicines Agency (EMA). These reports form the basis
of the corresponding HMPC-Monographs and together help the EU
member states to harmonize their – subsequently largely autonomous
–decisions on a speciﬁc registration. They also contain reference lists
and, therefore, in each case reﬂect the underlying scientiﬁc state of
knowledge.
If one scans these Assessment Reports, it emerges that a part of the
evidence available has been systematically omitted. The inclusion of all
potentially available sources and their methodically and conceptually
adequate appraisal can yield important new evidence for clinical
application, however, with consequences for the therapeutic practice
and the use of herbal medicines. Otherwise, the concept of “traditional
use” could, for example, easily be misinterpreted as demonstrating a
lack of evidence (Fig. 1)
Using the example of the monographs approved by the National
Health Products Directorate (NHPD) in Canada, John K. Crellin has
impressively demonstrated the consequences that can ensue when
literary references taken from older pharmacopoeias or other pharma-
ceutical reference sources are used inconsistently or adopted without
scrutiny for developing Assessment Reports on traditional herbal
medicinal products (Crellin, 2008). Similarly, the ﬁndings of Klose
et al. reveal problems in the safety assessment if sources from diverse
medical and pharmaceutical contexts are used without careful diﬀer-
entiation (Klose et al., 2016). The regular review and updating of
HMPC monographs every ﬁve years does not resolve the fundamental
problem of historical evidence (or in this case the lack thereof) unless
such omissions are rectiﬁed in each case.
The registration practice applied so far has shown, moreover, that
the “proof of tradition”-aspect is dealt with diﬀerently in each of the
member states. Reasons for this include the vague wording in the
regulation and the problems linked to the concept of plausibility
essential in the context of safety and eﬃcacy, and linked with the
attributes “traditional” or “longstanding” (Heinrich, 2015).
The speciﬁed period of at least 30 years for proof of tradition is
entirely arbitrary (Moreira et al., 2014; Australian Government, 2014).
In practice this period often proves to be either too short or too long,
depending on whether it refers to herbal medicines, herbal substances
or herbal preparations. This randomly chosen timeframe (as a mini-
mum requirement) also aﬀects the medical use of the medicinal
product to be registered.
In 2013, Müller reported the traditional use of nine species as well
as that of honey for the treatment of wounds, burns, ulcers, and
dermatoses. For Lawsonia inermis L. (Lythraceae); Punica granatum
L. (Lythraceae); Equisetum sp. (Equisetaceae); Commiphora myrrha
(Nees) Engl. (Burseraceae / listed as Commiphora molmol); Nigella
sativa L. (Ranunculaceae); Trigonella foenum-graecum L. (Fabaceae
s.str / Leguminosae); Coriandrum sativum L. (Apiaceae), Myrtus
communis L. (Myrtaceae), and Sanicula europaea L. (Apiaceae)1 he
Fig. 1. Establishing evidence for THMP.
1 The taxonomic validation of the species is based on http://mpns.kew.org/mpns-
portal/ and www.theplantlist.org and was done by the authors of this paper.
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could establish evidence of a continuous traditional use over centuries
up to the present day. For example, myrrh (C. myrrha) was ﬁrst
recorded for the treatment of wounds in the Papyrus Ebers 1550 BCE
(cf. Müller, 2013, 176). Ancient Egyptian Papyri describe its use
against burns, ulcers, and dermatoses as well. Around 450 BCE myrrh
occurs in "The Histories" of Herodotus as a vulnerary; it was prominent
among the wound treatment agents of the Middle Ages and kept this
position continuously throughout all centuries (Müller, 2013, 170–
197). For example, it is mentioned in pharmacological and surgical
handbooks of the 1830s as useful for promoting granulation, treatment
of ecoriated gingiva and so on. This has been conﬁrmed in the famous
"Lehrbuch der biologischen Heilmittel" by Gerhard Madaus a hundred
years later (Madaus, 1938). Aside from stomatological indications in
Europe, the use of myrrh was more and more abandoned, while a lively
tradition of its use for wound treatment, in particular related to the
diabetic foot syndrome, continued in Arabic countries (Müller, 2013,
Alzahrani and Bakhtoma, 2010). This example shows the power of
historical research as a proof of use well beyond the 30 year period and
besides particular brands. These studies oﬀer many examples how an
extended time frame could oﬀer opportunities for an approach which
uses historical documents as a proof of use well beyond the 30 year
period.
Another example are the traditional uses of Crataegus spp. and
Leonurus sp. Schantz (2009) traced the medicinal use of Crataegus
spp. back to the work of Dioscorides (c. 40–90 CE) and shows that
there is a continuous tradition through the Middle Ages and Early
Modern times up to nineteenth and twentieth centuries. Schantz
includes 58 written sources covering uses of Crataegus spp. for the
period 100 BCE up to 2005 and 44 for Leonurus sp. since the Middle
Ages. Crataegus, for example, has not only been used for complaints of
the heart, which is the predominant indication today, but against a
variety of diseases like gastrointestinal disorders. Not all of these could
be conﬁrmed by recent bio-scientiﬁc or clinical studies and this would
in fact not be required under the THMPD, where plausibility of a
medical use needs to be demonstrated but not eﬃcacy. The continuous
use over two thousand years unveiled by a professional evaluation of
historical sources provides a very profound basis for modern uses,
which could be explored further. It also demonstrates a considerable
degree of safety. The same is the case with Leonurus sp. which has a
continuous tradition for cardiac indications from the Middle Ages.
With regards to proof of safety all material available (this applies to
the past as well) needs to be assessed and evaluated as a matter of
principle. The nephrotoxicity of the Aristolochia species, for instance
(Michl et al., 2014), led to the infamous incident involving Belgian
slimming preparations. However, this had been a known factor since
1815, if not even since antiquity, and has been described in unequi-
vocal terms. (Scarborough, 2011).
5. Historical evidence as an essential requirement
For the authorization or registration of medicines, the European
and German medicine laws stipulate two diﬀerent procedures for
providing evidence-based proof of eﬃcacy and safety. In the registra-
tion process, on the one hand, evaluation respects the hierarchy of
evidence, which, for instance, is also used by the Cochrane
Collaboration (e.g. Cochrane GRADE: http://www.cochrane.de/de/%
C3%BCber-grade). On the other hand, there are, as a criterion for the
registration of traditional herbal medicines, these aspects of eﬃcacy
and safety, demonstrated on the basis of “traditional use” and,
moreover, considered scientiﬁcally plausible. The regulatory
authorities only take the law as their point of reference. However, we
are undoubtedly dealing with scientiﬁcally evaluable data useful as
evidence for the use of the medicine in question, the only diﬀerence
being that, in this instance, in evaluating the methods a diﬀerent
scientiﬁc discipline (history) needs to be consulted. Evidence-based
medicine is open to the various kinds of scientiﬁc insights, including
those of epidemiology, medical sociology or the histories of pharmacy
and medicine (Sackett et al., 1997; Eichler et al., 2015). For questions
regarding the safety of use under practice conditions or the historical
origin of a treatment, the relevant scientiﬁc methods can provide
additional insights.
With the registration of Traditional Herbal Medicinal Products in
particular, safety of use (innocuousness) is a key aspect when assessing
the risk-beneﬁt ratio. Therefore, particular value is placed on the exact
scientiﬁc assessment of the data regarding “traditional” use, and on the
insights that may be gained in this process with respect to modes of
application, indications and possible side eﬀects etc. If, therefore,
“traditional use” is chosen as a basic criterion, as the law stipulates, it is
in our view essential that this traditional use is scientiﬁcally assessed
and evaluated, (Helmstädter and Staiger, 2014), even if at present the
law does not explicitly ask for this. This would also meet one of the
requirements set out by the WHO, which is “[to] identify sources of
evidence, whether historical, traditional or scientiﬁc, which support or
invalidate a particular therapy” (WHO Traditional Medicine Strategy
2014–2023)
6. Methodological recommendations for the proof of
tradition
There are plenty of guidelines and recommendations relating to
Section 39a of the German Medicinal Products Act in the publications
of the EMA and of the national regulatory authorities. However, in a
recommendation issued by the German Federal Institute for Drugs and
Medical Devices (Bundesinstituts für Arzneimittel und
Medizinprodukte, BfArM) one also ﬁnds the following statement,
which highlights the concern expressed in this contribution, “A great
diversity of documents are accepted as proof of tradition; applicants
can use their own creativity in collating their documents!” (BfArM
Arzneimittelzulassung). While ‘creativity’ may have a role to play in the
arts, the humanities, including history, require methodical procedures
(as do medicine and pharmacy which are both informed by the natural
sciences) which emphasize criteria such as plausibility, comprehensi-
bility, transparency and structure.
A critique of sources is a central aspect of history as a science. Any
transmitted record can be a source for the historian, but whether or not
it is useful depends on the question investigated. It is important to keep
in mind that the selection of sources in itself constitutes an interpreta-
tion. This applies as much to the history of pharmacy, as it does to
history in general.
The critical assessment of sources as the benchmark for historical
evidence has been standard procedure in the history for more than 200
years (Gierl, 2012). It consists of several stages.
The ﬁrst step is to establish external criteria: Is the source genuine?
Is it the author's own work? Is it original? Is it based on the author's
own observations or insights? How was the source transmitted (in its
original or in a secondary form)? Is it a (reliable) translation? (Müller,
2013; Pommerening, 2006).
The importance of such assessment criteria for plant monographs
which rely on more recent documents from the last thirty or forty years,
has been demonstrated by John K. Crellin, who has given examples
from North America. For example, the evidence from the various
editions of standard pharmaceutical texts has been chosen arbitrarily.
In some cases, only two citations from diﬀerent years were considered
suﬃcient as proof of continued use.
Often primary sources such as recipes or formulae are not sighted
but cited through secondary sources. They are not properly assessed or
scrutinized, an omission that can lead to mistakes and misinterpreta-
tions. The Herbal Materia Medica editions also reveal that sources
which are not cited in the original may contain – often quite serious –
mistranslations.
Bibliographies are often restricted to printed sources. Hand-written
sources, such as the partly preserved pharmaceutical records
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(Rezeptkopierbücher) from the mid-nineteenth century contain med-
icinal formulae, the patients’ names, also medicinal formulae the name
of the prescribing physician and the cost of the medicine dispensed, but
are not taken into consideration. Such unprinted sources have so far
not been drawn on to support the proof of tradition, even though they
can provide continual and detailed evidence regarding the dispensing
of a particular medicinal product over several centuries (Hoﬀmann,
2014, 94–105). Similarly, patients’ records form surgeries or hospitals
have not been considered (Dietrich-Daum et al., 2008).
The external veriﬁcation of sources is followed by an internal one
looking at the origin of a source: Who composed it, when, how, where
and for what purpose? Are there indications as to the author's
intentions? Has information been withheld? What is the source's
historical context, including economic, social and legal aspects? Are
there concepts, occurrences or personal information that remain
ambiguous?
Consequently, for the proof of tradition individual elements of
evidence need to be examined thoroughly in order to exclude idiosyn-
crasies. The authors of the citations also need to be scrutinized
regarding their intentions. What time and place did the author live
in? One also needs to understand who commissioned the source in
question. The overall aim is to create a broad pattern of observation
with the inclusion of primary sources (Crellin, 2008).
Once the sources have been veriﬁed one needs to ask how
instructive and relevant a source is for the original research question,
in this case, submitting proof of tradition for a registration procedure.
Eﬃcacy is proven by demonstrating its presence in concrete modalities
of application, while safety is proven by demonstrating the absence of
harmful eﬀects, in other words, source criticism requires diverse
approaches.
Importantly, can the data available, as a whole, yield suﬃcient
evidence for the safety and medicinal use of the medicine submitted for
registration? What kind of data is able to provide valid information?
This depends, for instance, on the product type (at an early or later
stage of a value chain) – plant, drug, extract – one is dealing with.
It also needs pharmaceutical expertise to establish whether, and to
what extent, historical sources yield information on the plant parts and
extraction methods used. Both have an important inﬂuence on the
product's composition. In this case the traditional use of a plant
without the inclusion of further details about its pharmaceutical
preparations is less informative.
The resin of the olibanum or frankincense tree (Boswellia serrata
L., Burseraceae) is a good example of an herbal medicine with well-
documented traditional use. Frankincense has been used since anti-
quity in medical systems in and outside of Europe (Stueker, 2006). The
indications documented include external applications, for instance, –
in wound care or for inﬂammatory and rheumatic conditions – which
mostly go back to Indian Ayurvedic medicine. These reports prompted
extensive pharmacological studies which demonstrated the botanical
drug's anti-inﬂammatory properties and led to the isolation of a speciﬁc
active metabolite: the boswellic acids (Abdel-Tawab, 2011; Ammon,
2016). However, no commercial frankincense preparation has been on
the market for more than thirty years in the European Union.
Consequently, despite this uninterrupted tradition of use and the
“plausible” eﬀect demonstrated in pharmacological and clinical experi-
ments, it has so far been impossible to register frankincense prepara-
tions in Germany.
The extended time period proposed here for the proof of tradition
should not go back further than the time of the ﬁrst publication, in
1735, of Systema Naturae, the multivolume standard work of the
botanist Carl Linnaeus (1708–1778). His classiﬁcation, which also uses
binomial designations for plants, forms the foundation of today's
biological nomenclature. At the same time, in order to avoid drawing
false conclusions regarding medical uses one needs to keep an eye on
the change of long-lived medical (body-) concepts (like the humoral
pathology).
With traditional uses that continue into the present time and for
which evidence needs to be supplied in the case of traditional herbal
medicinal products, one needs to understand what exactly the proof of
tradition relates to. Here, examinations are useful that make use of
epidemiological methods as well as the scientiﬁc preparation of data
arising from the medical and pharmaceutical practice. The relevant
literature can supply a wealth of material on how these examinations
need to be conducted to a very high standard. An important repository
of what can be considered modern historical sources is the European
Network of Centres for Pharmacoepidemiology and Pharmacovigilance
(ENCePP; http://www.encepp.eu/).
Pharmaceutical collections and standard reference works are an
important source of information and can support a well-founded proof
of tradition based on a broad selection of sources, but it is beyond the
scope of this article to list them. Some of these sources are now
available in digital format and can easily be accessed online (Mönnich,
2006). Studies from the history of pharmacy which contain chronolo-
gical bibliographies can also be a good starting point (Müller, 2013;
Schantz, 2009). On the whole, evaluation of the older literature needs
expertise and competence which can usually be found among the
representatives of both the history of medicine and the history of
pharmacy. It is essential that they are consulted for the proof of
tradition. There are initiatives in North America worth noting. John K.
Crellin, for instance, is taking the regulatory authorities to task. In his
opinion it is up to the authorities to make sure, when considering the
registration of an herbal medicine, that its proof of tradition is based on
evidence (“sound scholarship”, Crellin, 2008). In this context the EU
will need to develop a much sounder strategy. This is in the interest of
the consumers and the manufacturers. In the future it will contribute to
improving the quality of application and safety of use of herbal
medicines.
7. Conclusion
Just like with other therapies, the therapeutic use and formal
registration of Traditional Herbal Medicinal Products is largely based
on their longstanding tradition. Many institutions – both at a national
and European level – have contributed to this. For example, since 2004
the EMA committee for herbal medicinal products (HMPC) has made
important contributions to implementing the THMP directive, also by
assessing the scientiﬁc evidence for a large number of traditionally used
medicinal products, and in issuing respective monographs, but here we
argue that a more rigorous assessment of the historical data is
nevertheless consequential. In order to ensure that this therapeutic
use complies with the requirements of evidence-based medicine, it is
essential that all relevant data, not only those stipulated in the
regulatory provisions (30 years, product reference), are scientiﬁcally
assessed and evaluated.
Clearly, from among the natural, life and cultural sciences, the
scientiﬁc methods considered authoritative in each case, need to be
used. The same is the case with historical aspects. Despite of restriction
of the THR to the more recent past (i.e. the 30 years speciﬁed by the EU
Directive), historical evidence is essential and needs to be based on
sound scientiﬁc methods. Best practice is required to ensure that
patients will beneﬁt from the “best available evidence” that is the
hallmark of evidence-based medicine.
Acknowledgments
The authors would like to thank Prof. Dr. rer. nat. Werner Knöss
(BfArM, Bonn) for his critical review and suggestions.
Funding
This work was partly supported by the Kooperation
Phytopharmaka, Bonn, Germany, and the Robert Bosch Foundation,
Stuttgart, Germany
R. Jütte et al. Journal of Ethnopharmacology 207 (2017) 220–225
224
References
Abdel-Tawab, M., Werz, O., Schubert-Zsilavecz, M., 2011. Boswellia serrata: an overall
assessment of in vitro, preclinical, pharmakokinetic and clinical data. Clin.
Pharmacokinet. 50, 349–369.
Akzahrani, H.A., Bakhtoma, B.A., 2010. Top ten natural preparations for the treatment of
diabetic foot disorders. Wounds UK 6 (4), 18-26. Allensbach Survey, 2017, 〈http://
www.ifd-allensbach.de/uploads/tx_studies/7528_Naturheilmittel_2010.pdf〉
(Accessed 12 January 2017).
Allensbach Survey, 2017, 〈http://www.ifd-allensbach.de/uploads/tx_studies/7528_
Naturheilmittel_2010.pdf〉 (last accessed 12/1/2017).
Ammon, H.P., 2016. Boswellic acids and their role in chronic inﬂammatory diseases.
Adv. Exp. Med. Biol. 928, 291–327.
Arzneimittelgesetz, 2005. 〈https://dejure.org/gesetze/AMG/39b.html〉 (Accessed 29
September 2016).
Assmann A., 1994. Fluchten aus der Geschichte: die Wiedererﬁndung von Tradition vom
18. bis zum 20. Jahrhundert. Universität Bielefeld, 1994, 〈https://www.uni-
bielefeld.de/%28en%29/ZIF/Publikationen/Jahresberichte/1994-Assmann.pdf〉
(Accessed 12 January 2017).
Australian Government, Department of Health, 2014. (Ed.). Guidelines on the evidence
required to support indications for listed complementary medicines. Version 2.1,
July 2014, 〈https://www.tga.gov.au/publication/evidence-guidelines〉 (Accessed 29
January 2017).
Beckstein, M., 2017. The concept of a living tradition. Eur. J. Social. Theory 20 (4).
BfArM Arzneimittelzulassung; 〈http://www.bfarm.de/SharedDocs/Downloads/DE/
Arzneimittel/Zulassung/zulassungsarten/besTherap/amTrad/TradAM_FAQ.pdf?
__blob=publicationFile〉 (Accessed 4 October 2016).
Blumenberg, H., 1981. Die Lesbarkeit der Welt. Suhrkamp, Frankfurt am Main.
Brandt, A., 1958. Werkzeug des Historikers. W. Kohlhammer, Stuttgart.
Crellin, J, 2001. Social Validation: An historian’s look at complementary/alternative
medicine. Pharm. Hist. 31, 43–51.
Crellin, J., 2008. ‘Traditional use’. claims for herbs: the need for competent historical
research. Pharm. Hist. 38, 34–41.
Dietrich-Daum, E., Dinges, M., Jütte, R., Roilo, C. (Eds.), 2008. Arztpraxen im Vergleich
18. Jahrhundert. Studien Verlag, Innsbruck, 20.
Directive, 2004. 〈http://ec.europa.eu/health/ﬁles/eudralex/vol-1/dir_2004_24/dir_
2004_24_de.pdf〉 (Accessed 29 September 2016).
Dittmann, K., 2004. Tradition und Verfahren: Philosophische Untersuchungen zum
Zusammenhang von kultureller Überlieferung und kommunikativer Moralität. BoD
– Books on Demand.
Eichler, M., Pokora, R., Schwentner, L., Blettner, M., 2015. Evidenzbasierte Medizin.
Möglichkeiten und Grenzen. Dtsch. Ärzteblatt 112, A2190–A2192.
Gierl, M., 2012. Geschichte als Präzisierte Wissenschaft: Johann Christoph Gatterer und
die Historiographie des 18Jahrhunderts im ganzen Umfang. Frommann-holzboog,
Stuttgart.
Handler, R., Linnekin, J., 1984. Tradition. Genuine or Spurious? J. Am. Folk. 385,
273–290.
Heinrich, M., 2015. Quality and safety of herbal medical products: regulation and the
need for quality assurance along the value chains. Br. J. Clin. Pharmacol. 80, 62–66.
Heinrich, M., Pardo-de-Santayana, M., Kufer, J., Leonti, M., 2006. Ethnobotany and
ethnopharmacology – interdisciplinary links with the historical sciences. J.
Ethnopharmacol. 107, 157–160.
Helmstädter, A., Staiger, C., 2014. Traditional use of medicinal agents: a valid source of
evidence. Drug Discov. Today 19, 1–7.
Hobsbawm, E., Ranger, T., 1992. The Invention of Tradition. Cambridge University
Press, Cambridge.
Hoﬀmann, A., 2014. Arzneimittelkonsum und GeschlechtEine Historische Analyse zum
19. und. Jahrhundert. Franz Steiner Verlag, Stuttgart, 20.
IMS Health OTC®Report (EVP), 2015. 〈https://www.imshealth.com/ﬁles/web/
Germany/Marktbericht/IMS_Pharmamarktbericht_Juli_2015.pdf〉 (Accessed 12
January 2017).
Arzneimittelrecht Kommentar. In: Kloesel, A., Cyran, W. (Eds.), Deutscher Apotheker-
Verlag, Stuttgart..
Klose, P., Kraft, K., Lauche, R., Cramer, H., Dobos, G., Langhorst, J., 2016.
Berücksichtigung von Wechsel- und Nebenwirkungen bei pﬂanzlichen Arzneimitteln
in deutschen S3-Leitlinien der AWMF. Forsch. Komplementmed 23, 154–164.
Kügel, J., Müller, R.G., Hofmann, H.P. (Eds.), 2016. Arzneimittelgesetz.
Kommentarsecond ed. C. H. Beck, Munich.
Lardos, A., 2015. Historical approaches in ethnopharmacology. In: Heinrich, M., Jaeger,
A.K. (Eds.), Ethnopharmacology. Wiley, Chichester, 333–341.
Leonti, M., 2011. The future is written: impact of scripts on the cognition, selection,
knowledge and transmission of medicinal plant use and its implications for
ethnobotany and ethnopharmacology. J. Ethnopharmacol. 134, 542–555.
Madaus, G., 1938. Lehrbuch der Biologischen Heilmittel. Georg Thieme Verlag, Leipzig,
Germany.
Michl, J., Ingrouille, M., Simmonds, M., Heinrich, M., 2014. Naturally occurring
aristolochic acid analogues and their toxicities. Nat. Product. Rep. 31, 676–693.
Mönnich, M., 2006. Pharmaziehistorische Quellen im internet. Pharm. Ztg. 9, 1–11.
Moreira, D.L., Schaaf Teixeira, S., Monteiro, M.H., De-Oliveira, A.C., Paumgartten,
F.J.R., 2014. Traditional use and safety of herbal medicines. Rev. Bras. Farmacogn.
24, 248–257.
Müller, J., 2013. Pﬂanzen zur Wundbehandlung der mittelalterlichen arabischen
Heilkunde in der europäischen Tradition. Wissenschaftliche Verlagsgesellschaft,
Stuttgart.
Pommerening, T., 2006. Überlegungen zur Beurteilung der Wirksamkeit altägyptischer
Arzneimittel aus heutiger Sicht, In: Zibelius Chen, K. , Fischer-Elfert, H.W. (Eds.),
Von reichlich ägyptischem Verstande. Festschrift für Waltraud Guglielmi zum 65.
Geburtstag. Harrassowitz, Wiesbaden, pp. 103–112.
Popper, K., 1972. Towards a rational theory of tradition. In: Conjectures and Refutations.
The Growth of Scientiﬁc Knowledgefourth ed. Routledge and Kegan Paul, London.
Sackett, D.L., Rosenberg, W.M., Gray, J.A., Haynes, R.B., Richardson, W.S., 1997. Was
ist Evidenz-basierte Medizin und was nicht? Münch Med Wochenschr. 139,
644–645.
Scarborough, J., 2011. Ancient medicinal use of Aristolochia: birthwort's tradition and
toxicity. Pharm. Hist. 53, 3–20.
Schantz, P., 2009. Weißdorn und Herzgespann. Medizinhistorische Untersuchungen zur
europäischen Tradition dieser Arzneipﬂanzen vom Mittelalter bis zur Gegenwart.
Kassel University Press.
Shils, E., 1981. Tradition. University of Chicago Press, Chicago.
Stellungnahme des Wirtschafts- und Sozialausschusses zum dem Vorschlag für eine
Richtlinie des Europäischen Parlaments und des Rates zur Änderung der Richtlinie
2001/83/EG im Hinblick auf traditionelle pﬂanzliche Arzneimittel. Amtsblatt der
Europäischen Union 14.3.2003, C61/10, http://eur-lex.europa.eu/legal-content/
DE/TXT/?uri=CELEX%3A52002AE1007 (last access 14/3/2017).
Stueker, I., 2006. Weihrauch, ein altes Heilmittel im Neuen [!] Gewande. Medical
Dissertation, Hannover.
Tu, Y., 2016. Artemisinin – a gift from traditional chinese medicine to the world (nobel
lecture). Angew. Chem. Int. Ed. 35, 10210–10226.
Unschuld, P.U., 2015. Der nobelpreis für Medizin im Jahr 2015. Z. Phytother. 36,
279–283.
Vlietinck, A., Pieters, L., Apers, S., 2009. Legal requirements for the quality of herbal
substances and herbal preparations for the manufacturing of herbal medicinal
products in the European Union. Plant Med 75, 683–688.
Weick, K.E., 1995. Sensemaking in Organizations. Sage, London.
R. Jütte et al. Journal of Ethnopharmacology 207 (2017) 220–225
225
